News – Page 935 – Endpoints News

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

6 years ago

Ex-FDA commish Scott Gottlieb makes a quick jump back onto the money side of biotech

6 years ago

Array shares surge as PhIII sets the stage for FDA filing; FDA gives Avadel priority review

6 years ago

Affimed hangs onto Genentech alliance after dropping stranded PhI program as CSO exits

6 years ago

Another Eli Lilly oncology drug is in trouble, as Japan issues Verzenio safety warning

6 years ago

Drug regulators look to harmonize how they tackle innovation

6 years ago

Another gene therapy company launches with VC cash and a CRISPR tech to target toxic RNA

6 years ago

Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D

6 years ago

Novartis drums up anticipation for blockbuster-to-be with PhII data on asthma drug, beating Advair in head-to-head

6 years ago

David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal

6 years ago

Amgen offers to swallow Denmark-based drug discovery partner in $167M deal

6 years ago

Adimab team accuses prominent MIT investigator Ram Sasisekharan of ripping off antibodies and presenting them as his ...

6 years ago

Top AstraZeneca I/O exec jumps to Seattle Genetics as first CCO; Woodford fund downgraded as woes mount

6 years ago

Thanks to Supreme Court decision, Merck gets another chance to throw out Fosamax claims

6 years ago

Hercules vet launches a new life sciences lender with $400M to put into play

6 years ago

Google's life sciences sister plugs Big Pharma into the mainstream in a digital overhaul of the clinical trial ...

6 years ago

BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

6 years ago

Beleaguered Biogen faces the music as a rising chorus of critics push for a transformative approach to M&A

6 years ago

Germany's Evotec expands into biologics with up to $90M deal for Seattle's Just Biotherapeutics

6 years ago

PhIII setback mars Ocular's glaucoma drug/device, though company remains 'encouraged' by data breakdown

6 years ago

Merck bets $2.2B on a small cancer drug biotech, snatching it out of the IPO lineup

6 years ago

Merck's Keytruda fails triple negative breast cancer pivotal study

6 years ago

Additional backing arms Schrödinger with $110M in first venture round — shining a spotlight on its own pipeline

6 years ago

Takeda shares positive Phase IIIb data; NIA grant for Phase II study on new oral Alzheimer's treatment

6 years ago

First page Previous page 932 933 934935936 937 938 Next page Last page